Pirfenidone treatment of idiopathic pulmonary fibrosis
Pirfenidone is the first antifibrotic agent to be approved for the treatment of pulmonary fibrosis. Idiopathic pulmonary fibrosis (IPF) is one of the idiopathic interstitial pneumonias with the worst prognoses; approximately half of patients die within 3–5 years, and the need for an effective treatm...
Uloženo v:
| Hlavní autor: | |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publishing
2012-04-01
|
| Edice: | Therapeutic Advances in Respiratory Disease |
| On-line přístup: | https://doi.org/10.1177/1753465812436663 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|